Advances in COVID-19: the virus, the pathogenesis, and evidence-based control and therapeutic strategies

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

(2020) Manli Wang et al.   CELL RESEARCH

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China

(2020) Dawei Wang et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Genomic variance of the 2019‐nCoV coronavirus

(2020) Carmine Ceraolo et al.   JOURNAL OF MEDICAL VIROLOGY

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

(2020) Roujian Lu et al.   LANCET

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

(2020) Nanshan Chen et al.   LANCET

A pneumonia outbreak associated with a new coronavirus of probable bat origin

(2020) Peng Zhou et al.   NATURE

First Case of 2019 Novel Coronavirus in the United States

(2020) Michelle L. Holshue et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Novel Coronavirus from Patients with Pneumonia in China, 2019

(2020) Na Zhu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome

(2018) Verena Staedtke et al.   NATURE

Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology

(2017) Rudragouda Channappanavar et al.   Seminars in Immunopathology

Endothelial Cells Are Central Orchestrators of Cytokine Amplification during Influenza Virus Infection

(2011) John R. Teijaro et al.   CELL

Targeting Robo4-Dependent Slit Signaling to Survive the Cytokine Storm in Sepsis and Influenza

(2010) N. R. London et al.   Science Translational Medicine

The spike protein of SARS-CoV — a target for vaccine and therapeutic development

(2009) Lanying Du et al.   NATURE REVIEWS MICROBIOLOGY